Evidence-Based Summary
Matrixyl (palmitoyl pentapeptide-4, Pal-KTTKS) and GHK-Cu (copper tripeptide-1) are both promoted for collagen and skin repair, and both rest mainly on cell and animal research. Matrixyl's best-known human trial is a 93-woman split-face study run by Procter & Gamble that reported modest wrinkle improvement. GHK-Cu's human studies are older and mixed: a small post-laser study (13 completers) found no objective benefit, only a patient-rated one, and a 1994 diabetic-ulcer study tested a specific wound gel alongside intensive standard care. No study has compared the two. Neither is an FDA-approved drug; FDA does not pre-approve cosmetic ingredients. Note the naming trap: Matrixyl 3000 contains palmitoyl tripeptide-1 (Pal-GHK, without copper), not palmitoyl pentapeptide-4. GHK-Cu injections are a separate issue: FDA lists injectable GHK-Cu among compounding substances that may pose significant safety risks.
Quick Comparison: Matrixyl vs GHK-Cu
A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.
| Feature | Matrixyl | GHK-Cu |
|---|---|---|
| Class | Palmitoylated pentapeptide (Pal-Lys-Thr-Thr-Lys-Ser), synthetic | Copper complex of Gly-His-Lys, a peptide found naturally in the body |
| Proposed target | Fibroblasts: collagen and fibronectin production (cell studies) | Fibroblasts and wound tissue: connective-tissue build-up (cell and rat studies) |
| How it is used | Applied to the skin in creams and serums, usually daily | Applied to the skin in creams and gels; injected by some users without approval |
| U.S. regulatory status | Cosmetic ingredient; no FDA drug approval exists | Cosmetic ingredient; no FDA drug approval; injectable GHK-Cu on FDA's compounding safety-risk list |
| Strongest human evidence | 93-woman split-face trial, 12 weeks, manufacturer-run | 1994 randomized diabetic-ulcer study of a specific wound gel; small post-laser study with no objective benefit |
| Main safety concerns | Well tolerated in trials; few independent safety data | Topical use generally tolerated; FDA cites immunogenicity and impurity concerns and limited human data for injection |
| WADA status (2026) | Not named on the 2026 Prohibited List | Not named; S0 may apply to unapproved non-topical use, so athletes should seek anti-doping advice |
Two Routes to the Same Marketing Claim
Both peptides stimulated connective-tissue production in laboratory or animal experiments. Changes in collagen markers in a dish or a rat wound do not prove visible skin improvement in people.
Matrixyl (palmitoyl pentapeptide-4)
Primary Target: No defined receptor; acts on fibroblasts in culture
Affinity Profile: Collagen-fragment signal (KTTKS from type I procollagen)
KTTKS was the minimum procollagen fragment that stimulated collagen and fibronectin production in cultured cells (1993). The palmitoyl tail improved stability; in mouse skin the peptide reached outer layers but did not pass fully through.
GHK-Cu (copper tripeptide-1)
Primary Targets: No single receptor; copper-binding peptide
Affinity Profile: Binds copper(II) ions
In rat experimental wounds, GHK-Cu increased connective-tissue accumulation (1993). Proposed explanations involve copper delivery and fibroblast signalling; a 2026 review describes human evidence as sparse and inconsistently characterized.
Cosmetic Ingredients, with an Injection Warning for GHK-Cu
Checked 11 October 2026. FDA does not pre-approve cosmetic products or ingredients (except certain color additives). Neither peptide is an approved drug.
Matrixyl Status & Formulations
Sold as a cosmetic ingredient; companies are responsible for safety and labeling. Matrixyl 3000 is a different blend (palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7), so its evidence does not apply to palmitoyl pentapeptide-4.
GHK-Cu Status & Formulations
Sold as a cosmetic ingredient. For injectable routes, FDA lists GHK-Cu among bulk drug substances that may present significant safety risks in compounding, citing possible immune reactions from aggregation and peptide-related impurities and limited human safety data.
Critical Regulatory Distinction
Claims to heal wounds, treat disease or change skin structure can make a product a drug under FDA rules. A cosmetic listing is not an FDA approval, and topical evidence does not support injection.
Small Studies, Different Settings
No study has compared Matrixyl and GHK-Cu. The studies below differ in population, product and outcome, so their results cannot be ranked against each other.
Matrixyl: Matrixyl studies
In a 12-week, double-blind, split-face trial of 93 Caucasian women (2005), a moisturizer with pal-KTTKS improved measured wrinkles and fine lines versus the same moisturizer without it; all authors worked for Procter & Gamble. A 21-woman, three-arm trial (2023, university-run) reported favorable but preliminary results. A 2011 review noted few clinical studies and little skin-penetration data.
GHK-Cu: GHK-Cu studies
After CO2 laser resurfacing, a randomized study (2006) with 13 completers found no objective difference in redness, wrinkles or skin quality between regimens with and without GHK-Cu; only patient questionnaires favored GHK-Cu. A multicenter randomized, evaluator-blinded study (1994) reported better closure of diabetic foot ulcers with a GHK-copper gel added to debridement, pressure-relieving footwear and other standardized care. Neither is a general anti-aging trial.
Topical Use vs Injection
Topical use was tolerated in the published studies, but they were small and short. Safety on the skin says nothing about injecting the same ingredient.
Injectable GHK-Cu
FDA's compounding safety page lists GHK-Cu for injectable routes, citing potential immunogenicity from aggregation and peptide-related impurities, and limited human data. Cosmetic-grade or 'research' material is not made or tested for injection.
| Safety Consideration | Matrixyl | GHK-Cu |
|---|---|---|
| Tolerability in studies | Well tolerated in the 93-woman trial | Used after laser resurfacing and on ulcers without major safety signals reported in abstracts |
| Regulatory safety flag | None specific | Injectable GHK-Cu on FDA's compounding safety-risk list |
| Skin penetration | Reached outer layers in mouse skin; not fully through | Formulation-dependent; not well characterized in people |
What Matrixyl and GHK-Cu Have in Common
Where the two compounds overlap in biology, evidence or regulatory context.
Collagen-focused claims
Both are marketed for collagen support based mainly on cell and animal experiments.
Cosmetic, not drug
Neither has an FDA drug approval; FDA does not pre-approve cosmetic ingredients.
Thin human evidence
Each has only a few small human studies, often tied to a product or manufacturer.
Key Scientific & Clinical Differences
Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.
Origin
GHK occurs naturally in the body; Matrixyl's KTTKS is a procollagen fragment made synthetically with a fatty-acid tail.
Type of human study
Matrixyl was tested for cosmetic wrinkles; GHK-Cu's key studies were in post-laser skin and diabetic ulcers.
Injection risk
GHK-Cu is also sold for injection, and FDA has flagged injectable GHK-Cu; Matrixyl is used topically.
Name confusion
Matrixyl 3000 contains Pal-GHK (no copper), which is a different ingredient from both Matrixyl and GHK-Cu.
Scientific Comparison vs Clinical Recommendations
Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.
Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.
Approved Uses vs Online Claims
A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.
GHK-Cu injections rebuild collagen and reverse aging
Not supportedFDA lists injectable GHK-Cu among compounding substances that may present significant safety risks.
Human evidence is topical, small and mixed. No controlled trial shows injected GHK-Cu is safe or effective.
Matrixyl is clinically proven to reduce wrinkles
Partly supportedCosmetic claims are not FDA-reviewed efficacy claims.
A manufacturer-run 93-woman trial showed modest improvement over 12 weeks; independent, larger trials are lacking.
Matrixyl 3000 is a copper peptide
Not supportedIngredient names on labels identify different substances.
Matrixyl 3000 contains palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7, not a copper complex and not palmitoyl pentapeptide-4.
Evidence Strength Across Clinical Domains
Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.
Facial wrinkles (topical)
Matrixyl has small, partly manufacturer-run trials; GHK-Cu's post-laser study found no objective wrinkle benefit.
Wound healing
One older randomized study of a specific GHK-copper gel in diabetic ulcers; Matrixyl has no wound trials.
Mechanism in living skin
Collagen effects come from cell cultures and rat wounds.
Injection
No controlled human evidence for injecting either peptide.
What Research Still Doesn’t Tell Us
Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.
Head-to-head comparison
No study has compared these ingredients in the same population.
Independent replication
Matrixyl's main trial was manufacturer-run; GHK-Cu's key studies are decades old and product-specific.
Penetration and dose-response
How much of either peptide reaches living skin cells from a cream is poorly characterized.
Route-specific safety
The safety of injecting GHK-Cu has not been established in controlled studies.
Related Compound Profiles
Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.
Related Educational Resources
Scientific & Regulatory References
Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.
-
Randomized split-face trial (manufacturer-run)
Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin.All authors were Procter & Gamble employees; 93 women, 12 weeks.
-
Small randomized three-arm trial
Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet.21 women in three groups, 8 weeks.
-
Cell research
A pentapeptide from type I procollagen promotes extracellular matrix production.
-
Laboratory skin study (mouse)
Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS).
-
Review
Topically applied KTTKS: a review.
-
Human skin permeation study
Permeation behaviour of cosmetic actives into the human stratum corneum.Describes Matrixyl 3000 as palmitoyl tripeptide-1 (Pal-GHK) plus palmitoyl tetrapeptide-7; three volunteers; two authors employed by a cosmetics company.
-
Randomized topical study
Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.13 patients completed; objective outcomes showed no between-group difference.
-
Randomized evaluator-blinded wound study
Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.
-
Animal research
In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds.
-
Review
GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap.Review, not primary clinical evidence.
-
FDA safety page
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksLists GHK-Cu for injectable routes; content current as of 22 April 2026; checked 11 October 2026.
-
FDA regulatory explanation
Cosmetics & U.S. LawExplains that FDA does not pre-approve cosmetic products or ingredients, other than certain color additives.
-
FDA regulatory explanation
Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)Intended use, including claims to treat disease or change body structure or function, can make a product a drug.